Aireen

𝗔𝗜 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝘀 𝗼𝗳𝘁𝗲𝗻 𝗳𝗿𝗮𝗺𝗲𝗱 𝗮𝘀 “𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝘀𝘂𝗽𝗽𝗼𝗿𝘁” 𝗳𝗼𝗿 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁𝘀. 𝗕𝘂𝘁 𝘁𝗵𝗲 𝗿𝗲𝗮𝗹 𝘀𝘆𝘀𝘁𝗲𝗺-𝗹𝗲𝘃𝗲𝗹 𝗶𝗺𝗽𝗮𝗰𝘁 𝘀𝘁𝗮𝗿𝘁𝘀 𝘄𝗵𝗲𝗻 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗔𝗜 𝗰𝗮𝗻 𝘀𝗮𝗳𝗲𝗹𝘆 𝗺𝗼𝘃𝗲 𝗿𝗼𝘂𝘁𝗶𝗻𝗲, 𝗵𝗶𝗴𝗵-𝘃𝗼𝗹𝘂𝗺𝗲 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗯𝗲𝘆𝗼𝗻𝗱 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 𝗿𝗼𝗼𝗺𝘀. That is where Aireen is focused. 𝗔𝗶𝗿𝗲𝗲𝗻 𝗶𝘀 𝗮𝗻 𝗘𝗨-𝗠𝗗𝗥 𝗖𝗹𝗮𝘀𝘀 𝗜𝗜𝗯 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗮𝘂𝘁𝗼𝗻𝗼𝗺𝗼𝘂𝘀 𝗔𝗜 𝗳𝗼𝗿 𝗿𝗲𝘁𝗶𝗻𝗮𝗹 𝗳𝘂𝗻𝗱𝘂𝘀 𝗶𝗺𝗮𝗴𝗲 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀. Its certified DR and AMD modules can be operated by any healthcare professional — with no on-site ophthalmologist required. One non-invasive 45° fundus image can deliver independent clinical insights in seconds, without specialist review. 𝗙𝗼𝗿 𝗼𝘃𝗲𝗿𝗯𝘂𝗿𝗱𝗲𝗻𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘀𝘆𝘀𝘁𝗲𝗺𝘀, 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀. Routine diabetic retinopathy and age-related macular degeneration screening should not depend on already scarce specialist capacity. Eye clinics, diabetology departments, optical retail chains, and community health hubs can all become access points for certified retinal screening. The result: faster answers for patients, lower cost per screening, better adherence, and more specialist time reserved for complex care. This is not AI replacing clinicians. It is AI removing bottlenecks so clinicians can do the work only they can do. 𝗦𝗰𝗮𝗹𝗶𝗻𝗴 𝗰𝗮𝗿𝗲 𝗳𝗼𝗿 𝗺𝗶𝗹𝗹𝗶𝗼𝗻𝘀. 𝗜𝗻𝘀𝘁𝗮𝗻𝘁𝗹𝘆. Learn more at aireen.com #DigitalHealth #Ophthalmology #Screening #DiabeticRetinopathy #MedTech #Aireen

𝗢𝗻𝗲 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. 𝗙𝗶𝘃𝗲 𝘁𝗮𝗶𝗹𝗼𝗿𝗲𝗱 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀. Healthcare efficiency is not created by adding more steps. It is created by moving routine, 𝗵𝗶𝗴𝗵-𝘃𝗼𝗹𝘂𝗺𝗲 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗰𝗹𝗼𝘀𝗲𝗿 𝘁𝗼 𝘁𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 — with certified technology teams can trust. Aireen supports different healthcare segments with one EU-MDR Class IIb certified autonomous AI platform for retinal fundus image analysis. 𝗙𝗼𝗿 𝗼𝗽𝗵𝘁𝗮𝗹𝗺𝗼𝗹𝗼𝗴𝗶𝘀𝘁𝘀 𝗲𝘆𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝘀: shift routine DR and AMD screening away from specialist bottlenecks. 𝗙𝗼𝗿 𝗱𝗶𝗮𝗯𝗲𝘁𝗼𝗹𝗼𝗴𝘆 𝗮𝗻𝗱 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗱𝗲𝗽𝗮𝗿𝘁𝗺𝗲𝗻𝘁𝘀: screen patients where chronic disease care already happens. 𝗙𝗼𝗿 𝗼𝗽𝘁𝗶𝗰𝗮𝗹 𝗿𝗲𝘁𝗮𝗶𝗹 𝗰𝗵𝗮𝗶𝗻𝘀: expand into community-based preventive health with near-instant results. 𝗙𝗼𝗿 𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗽𝗮𝘆𝗲𝗿𝘀 𝗮𝗻𝗱 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀: increase access while reducing cost per screening. 𝗙𝗼𝗿 𝗳𝘂𝗻𝗱𝘂𝘀 𝗰𝗮𝗺𝗲𝗿𝗮 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗼𝗿𝘀: add certified AI value to existing imaging workflows. One non-invasive 45° retinal image can generate multiple independent clinical insights in seconds — without specialist review on site. Today, Aireen offers certified modules for Diabetic Retinopathy and Age-related Macular Degeneration, with further indications in development. The opportunity is clear: make screening more accessible, more scalable, and more efficient — while freeing specialists to focus on complex care. 𝗦𝗰𝗮𝗹𝗶𝗻𝗴 𝗰𝗮𝗿𝗲 𝗳𝗼𝗿 𝗺𝗶𝗹𝗹𝗶𝗼𝗻𝘀. 𝗜𝗻𝘀𝘁𝗮𝗻𝘁𝗹𝘆. Learn more at aireen.com #DigitalHealth #Ophthalmology #AI #Screening #DiabeticRetinopathy

Summer is peak season for sunglasses, travel lenses — and a stronger community health role for optical retail. ☀️ 𝗙𝗼𝗿 𝗼𝗽𝘁𝗶𝗰𝗮𝗹 𝘀𝘁𝗼𝗿𝗲 𝗼𝘄𝗻𝗲𝗿𝘀 𝗮𝗻𝗱 𝗰𝗵𝗮𝗶𝗻 𝗺𝗮𝗻𝗮𝗴𝗲𝗿𝘀: An optical store can turn into a community health hub! WHO estimates that at least 2.2 billion people worldwide live with vision impairment. Diabetes and AMD add growing pressure on eye-care pathways — while specialist capacity remains limited across many regions. 𝗔𝗶𝗿𝗲𝗲𝗻 𝗵𝗲𝗹𝗽𝘀 𝗼𝗽𝘁𝗶𝗰𝗮𝗹 𝗿𝗲𝘁𝗮𝗶𝗹𝗲𝗿𝘀 𝗯𝗿𝗶𝗻𝗴 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗮𝘂𝘁𝗼𝗻𝗼𝗺𝗼𝘂𝘀 𝗿𝗲𝘁𝗶𝗻𝗮𝗹 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗰𝗹𝗼𝘀𝗲𝗿 𝘁𝗼 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀. With one non-invasive 45° fundus scan, Aireen delivers independent clinical insights in seconds — without specialist review. Certified modules available today: Diabetic Retinopathy and Age-related Macular Degeneration. With more to come. 𝗔𝗶𝗿𝗲𝗲𝗻 𝗶𝘀 𝗮𝗻 𝗘𝗨-𝗠𝗗𝗥 𝗖𝗹𝗮𝘀𝘀 𝗜𝗜𝗯 𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗮𝘂𝘁𝗼𝗻𝗼𝗺𝗼𝘂𝘀 𝗔𝗜 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲, 𝗖𝗘 𝟮𝟮𝟲𝟱. 𝗜𝘁 𝗰𝗮𝗻 𝗯𝗲 𝘂𝘀𝗲𝗱 𝗯𝘆 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗮𝗻 𝗼𝗻-𝘀𝗶𝘁𝗲 𝗼𝗽𝗵𝘁𝗵𝗮𝗹𝗺𝗼𝗹𝗼𝗴𝗶𝘀𝘁, 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗳𝗮𝘀𝘁, 𝗰𝗼𝗻𝘀𝗶𝘀𝘁𝗲𝗻𝘁 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲. For optical chains, that means: • shorter referral bottlenecks   • near-instant results   • stronger customer adherence   • a differentiated in-store health service   • specialists focused on complex cases  𝗧𝗵𝗶𝘀 𝗶𝘀 𝗵𝗼𝘄 𝗼𝗽𝘁𝗶𝗰𝗮𝗹 𝗿𝗲𝘁𝗮𝗶𝗹 𝗰𝗮𝗻 𝗲𝘃𝗼𝗹𝘃𝗲 𝗶𝗻𝘁𝗼 𝗮 𝘁𝗿𝘂𝘀𝘁𝗲𝗱 𝗽𝗿𝗶𝗺𝗮𝗿𝘆-𝗰𝗮𝗿𝗲 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝘁𝘆 𝗵𝘂𝗯. Go to https://lnkd.in/dDiZa7gm and evolve your optical store into a community health hub with us! Scaling care for millions. Instantly. Learn more at https://lnkd.in/dDiZa7gm #OpticalRetail #DigitalHealth #Ophthalmology #AI #Screening #DiabeticRetinopathy #Age-related_Macular_Degeneration

𝗔𝗶𝗿𝗲𝗲𝗻 𝗶𝘀 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗘𝗔𝗦𝗗 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗠𝗶𝗹𝗮𝗻𝗼 𝗶𝗻 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿! From 28 September to 2 October 2026, the 62nd Annual Meeting of the European Association for the Study of Diabetes will bring together the diabetes community to discuss what better, earlier, and more scalable care can look like. 𝗖𝗼𝗺𝗲 𝗺𝗲𝗲𝘁 𝘂𝘀 𝘁𝗵𝗲𝗿𝗲. Diabetic retinopathy screening is essential — but in many care pathways, access to specialist review remains a bottleneck. Patients wait. Clinics carry growing volumes. Ophthalmologists are pulled into routine screening instead of complex care. Aireen helps change that. Our EU-MDR Class IIb certified autonomous AI analyses retinal fundus images for Diabetic Retinopathy and Age-related Macular Degeneration in seconds — without on-site ophthalmologist review. One non-invasive 45° fundus image → multiple independent clinical insights. Usable by any healthcare professional. Integrated with PACS/DICOM workflows. Governed under IEC 27001:2023. For diabetology teams, internal medicine departments, eye clinics, optical retail networks, payers, and fundus camera partners, this is a practical way to scale screening capacity while keeping specialists focused where they are needed most. 𝗦𝗰𝗮𝗹𝗶𝗻𝗴 𝗰𝗮𝗿𝗲 𝗳𝗼𝗿 𝗺𝗶𝗹𝗹𝗶𝗼𝗻𝘀. 𝗜𝗻𝘀𝘁𝗮𝗻𝘁𝗹𝘆. See you in Milano. Learn more at www.aireen.com #EASD2026 #DiabeticRetinopathy #DigitalHealth #Ophthalmology #AI #Screening

🌍 𝗥𝗲𝘁𝗶𝗻𝗮𝗹 𝗔𝗜 𝗶𝗻 𝘁𝗵𝗲 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗮𝘁 𝗖𝗘𝗗𝗔 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗗𝘂𝘀𝘀𝗲𝗹𝗱𝗼𝗿𝗳! We are thrilled to share the outstanding presence and impact of Aireen’s AI technology at the Central European Diabetes Association (CEDA) Congress 2026 in Düsseldorf, beautifully organized by the Deutsches Diabetes-Zentrum (DDZ). Our non-invasive AI retinal screening tool was highlighted in groundbreaking research, showing how looking into the eye can, apart from automatically detecting diabetic retinopathy and Age-related Macular Degeneration, open a powerful window into systemic cardiometabolic health. 🔬 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝗲𝗱 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 & 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻𝘀: • Dr. Sorina Ispas, MD PhD, presented a vital poster utilizing Aireen technology titled "Artificial Intelligence-Based Retinal Screening for Cardiometabolic Prevention: A 3-Month Real-World Evidence Study". 𝗧𝗵𝗶𝘀 𝗶𝗺𝗽𝗮𝗰𝘁𝗳𝘂𝗹 𝘄𝗼𝗿𝗸 𝘄𝗮𝘀 𝗰𝗼𝗻𝗱𝘂𝗰𝘁𝗲𝗱 𝘂𝗻𝗱𝗲𝗿 𝘁𝗵𝗲 𝗲𝘅𝗽𝗲𝗿𝘁 𝗺𝗲𝗻𝘁𝗼𝗿𝘀𝗵𝗶𝗽 𝗼𝗳 𝗣𝗿𝗼𝗳. 𝗠𝗮𝗻𝗳𝗿𝗲𝗱𝗶 𝗥𝗶𝘇𝘇𝗼, 𝘄𝗵𝗼 𝘄𝗮𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹𝗹𝘆 𝗶𝗻𝗮𝘂𝗴𝘂𝗿𝗮𝘁𝗲𝗱 𝗮𝘀 𝘁𝗵𝗲 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 𝗼𝗳 𝗖𝗘𝗗𝗔 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗻𝗲𝘅𝘁 𝟰 𝘆𝗲𝗮𝗿𝘀! 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀, 𝗣𝗿𝗼𝗳. 𝗥𝗶𝘇𝘇𝗼! • Dr. Viviana Maggio achieved a double milestone! She authored a second poster featuring Aireen technology titled "Artificial Intelligence-Based Retinal Screening and Ocular Parameters in Cardiometabolic Disease: An Ophthalmologist-Confirmed RWE Study". Furthermore, she was invited as an oral speaker to present her compelling insights on the "Cardiometabolic Effects of GIP/GLP-1 Receptor Agonists in Subjects with Obesity and Type 2 Diabetes." • A special thank you to the brilliant minds making up Prof. Rizzo’s research team, including Angelo Maria Patti and Elena Muratore, whose collaborative efforts continue to validate the critical role of AI in early screening and patient care. 💡 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀 The data presented confirms that integrating AI-based retinal assessment into cardiometabolic prevention programs enables timely, real-world interventions. By connecting glycemic burden and vascular dysfunction to AI-detected retinal alterations, we are moving closer to a future of comprehensive, non-invasive risk management. A massive thank you to @Prof. Manfredi Rizzo, Dr. Sorina Ispas, Viviana Maggio, and the entire team for their dedication to clinical excellence and for leveraging Aireen to push the boundaries of metabolic medicine. 🔗 Learn more about our mission to prevent complications through advanced AI screening at aireen.com. #Aireen #CEDA2026 #DiabetesResearch #CardiometabolicHealth #MedicalAI #RetinalScreening #DigitalHealth #DDZDusseldorf

🚀 Just back from an exciting week at KIMES 2026 in Seoul with the EU Business Hub mission! Aireen proudly showcased our AI-powered retinal screening solution at the European Pavilion. We had a strong booth presence and conducted several high-impact meetings with Korean distributors, key stakeholders, and potential strategic partners. Exciting conversations about bringing non-invasive, early detection of chronic diseases to not only the Korean market. Big thanks to the EU Business Hub - Japan and the Republic of Korea team for making it happen! #KIMES2026 #Aireen #MedTech #AIinHealthcare #EUinKorea #BusinessMission

Aireen 𝗶𝗻 𝗢𝗽𝗵𝘁𝗵𝗮𝗹𝗺𝗼𝗹𝗼𝗴𝘆: 𝗪𝗵𝗲𝗿𝗲 𝗘𝗮𝗿𝗹𝘆 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 𝗠𝗮𝗸𝗲𝘀 𝘁𝗵𝗲 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 Aireen is expanding its reach into ophthalmology, focusing on the early diagnosis of Age-Related Macular Degeneration (#𝗔𝗠𝗗). This condition is among the leading causes of irreversible vision loss in seniors. This is why screening the older population is so critical. Furthermore, because AMD can have a hereditary component, relatives of patients and anyone with a family history of the disease need to undergo regular #𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴. Our collaboration with the MediPort oční ambulance diagnostic center demonstrates how artificial intelligence can naturally integrate into 𝗱𝗮𝗶𝗹𝘆 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 and provide real value by: - Speeding up the diagnostic process. - Increasing physician confidence when evaluating findings. - Improving the accessibility of preventive examinations. "𝘛𝘩𝘦 𝘤𝘰𝘭𝘭𝘢𝘣𝘰𝘳𝘢𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩 𝘈𝘪𝘳𝘦𝘦𝘯 𝘢𝘭𝘭𝘰𝘸𝘴 𝘶𝘴 𝘵𝘰 𝘪𝘥𝘦𝘯𝘵𝘪𝘧𝘺 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘵 𝘳𝘪𝘴𝘬 𝘰𝘧 𝘈𝘔𝘋 𝘢𝘵 𝘢 𝘮𝘶𝘤𝘩 𝘦𝘢𝘳𝘭𝘪𝘦𝘳 𝘴𝘵𝘢𝘨𝘦. 𝘈𝘵 𝘵𝘩𝘦 𝘴𝘢𝘮𝘦 𝘵𝘪𝘮𝘦, 𝘪𝘵 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘴𝘵𝘳𝘦𝘢𝘮𝘭𝘪𝘯𝘦𝘴 𝘵𝘩𝘦 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘴𝘴 𝘢𝘯𝘥 𝘩𝘦𝘭𝘱𝘴 𝘳𝘦𝘭𝘪𝘦𝘷𝘦 𝘰𝘷𝘦𝘳𝘣𝘶𝘳𝘥𝘦𝘯𝘦𝘥 𝘦𝘺𝘦 𝘤𝘭𝘪𝘯𝘪𝘤𝘴. 𝘈𝘴 𝘢 𝘴𝘤𝘳𝘦𝘦𝘯𝘪𝘯𝘨 𝘵𝘰𝘰𝘭, 𝘈𝘪𝘳𝘦𝘦𝘯 𝘤𝘢𝘯 𝘦𝘧𝘧𝘦𝘤𝘵𝘪𝘷𝘦𝘭𝘺 𝘢𝘯𝘢𝘭𝘺𝘻𝘦 𝘢 𝘱𝘢𝘵𝘪𝘦𝘯𝘵'𝘴 𝘤𝘰𝘯𝘥𝘪𝘵𝘪𝘰𝘯 𝘸𝘪𝘵𝘩𝘪𝘯 10 𝘴𝘦𝘤𝘰𝘯𝘥𝘴; 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘱𝘳𝘰𝘤𝘦𝘴𝘴 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘵𝘢𝘬𝘦𝘴 𝘢 𝘮𝘢𝘹𝘪𝘮𝘶𝘮 𝘰𝘧 3 𝘮𝘪𝘯𝘶𝘵𝘦𝘴. 𝘐𝘵 𝘪𝘴 𝘤𝘭𝘦𝘢𝘳 𝘵𝘩𝘢𝘵 𝘢 𝘥𝘰𝘤𝘵𝘰𝘳 𝘤𝘰𝘶𝘭𝘥 𝘯𝘦𝘷𝘦𝘳 𝘩𝘢𝘯𝘥𝘭𝘦 𝘴𝘶𝘤𝘩 𝘢 𝘩𝘪𝘨𝘩 𝘷𝘰𝘭𝘶𝘮𝘦 𝘰𝘧 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘭𝘰𝘯𝘦 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 𝘢𝘯 𝘈𝘐 𝘵𝘰𝘰𝘭 𝘭𝘪𝘬𝘦 𝘈𝘪𝘳𝘦𝘦𝘯," says Andrea Janekova, MD, FEBO, FEBOS-CR, Lead Physician at Oční centrum Praha and Medical Specialist at the MediPort oční ambulance 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 𝗘𝘆𝗲 𝗖𝗮𝗿𝗲 𝗖𝗲𝗻𝘁𝗲𝗿. 𝗪𝗵𝘆 𝗶𝘀 𝘁𝗵𝗶𝘀 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁?  With AMD, time is of the essence. The earlier the disease is detected, the better the chance of slowing its progression and preserving the patient's quality of life. AI technology does not replace the role of the doctor; instead, it becomes a powerful tool in their hands. 𝗦𝘁𝗮𝘁𝗶𝘀𝘁𝗶𝗰𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗖𝘇𝗲𝗰𝗵 𝗥𝗲𝗽𝘂𝗯𝗹𝗶𝗰/𝗪𝗼𝗿𝗹𝗱/𝗘𝗨/𝗨𝗦: 𝗣𝗿𝗲𝘃𝗮𝗹𝗲𝗻𝗰𝗲 𝗼𝗳 𝗔𝗠𝗗 𝗶𝗻 𝘁𝗵𝗲 𝗽𝗼𝗽𝘂𝗹𝗮𝘁𝗶𝗼𝗻: 0.5K/200M/67M/20M The partnership between Aireen and the MediPort oční ambulance confirms the potential of AI in ophthalmology — from prevention to managing the growing demand for eye care. #Ophthalmology #AIvMedicine #Prevention #DigitalHealth #AI #AMD #HealthTech

𝗥𝗲𝘃𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝗶𝘇𝗶𝗻𝗴 𝗗𝗶𝗮𝗯𝗲𝘁𝗶𝗰 𝗥𝗲𝘁𝗶𝗻𝗼𝗽𝗮𝘁𝗵𝘆 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴: 𝗔𝗶𝗿𝗲𝗲𝗻 𝘅 𝗢𝗽𝘁𝗼𝗺𝗲𝗱 🚀 We are thrilled to announce a major milestone in the future of digital health! Optomed Plc 𝗟𝘂𝗺𝗼 is now officially approved for 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗔𝗶𝗿𝗲𝗲𝗻’𝘀 𝗔𝗜 𝗮𝗹𝗴𝗼𝗿𝗶𝘁𝗵𝗺 for diabetic retinopathy (DR) screening in the EU. 🇪🇺 This strategic partnership combines Optomed Plc’s world-class handheld imaging with Aireen’s MDR Class IIb CE-marked AI to bring specialist-level diagnostics directly to primary care and mobile screening programs. Why this matters: 𝗣𝗿𝗼𝘃𝗲𝗻 𝗔𝗰𝗰𝘂𝗿𝗮𝗰𝘆: A recent study in Diabetes Technol Ther. (2025) confirmed a 94.8% sensitivity and 92.7% overall accuracy using this combined solution. 𝗔𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆: We are moving screening from the specialist's office to the patient's front door. 𝗦𝗰𝗮𝗹𝗮𝗯𝗶𝗹𝗶𝘁𝘆: This is just the beginning. We are building a platform to address a wider range of retinal and systemic diseases. As our CEO, Jiří Kuchyňa, puts it: "The portability of Optomed Lumo combined with Aireen’s AI has the potential to transform how and where retinal screening is delivered." Together, we are scaling care for millions. Instantly. https://lnkd.in/dw4vevGC

Haló, haló! Tady parta z Channel Lab! Přidáváme se k velkému zástupu přejících a přejeme všem krásné prožití vánočních svátků. Prožijte je s radostí a v tolik potřebném klidu. A také hodně štěstí a lásky, protože takových darů není nikdy dost. Do nového roku přejeme, ať nás spojuje především to nejcennější - zdraví! #ChannelLab #NeuronaLab #Molecula #Aireen #GenomeX